Stockscreener 앱 받기
0.47
4.44%
0.02
전일 마감가:
$0.45
열려 있는:
$0.4549
하루 거래량:
5.81M
Relative Volume:
0.89
시가총액:
$109.59M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.6267
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-32.88%
1개월 성능:
-31.42%
6개월 성능:
-77.07%
1년 성능:
-22.79%
1일 변동 폭
$0.449
$0.4879
1주일 범위
$0.4111
$0.7624
52주 변동 폭
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.47 | 160.48M | 52.29M | -134.84M | -117.11M | -0.75 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Sangamo Therapeutics prices $23M securities offering - MSN
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus
Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - BioSpace
Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria
Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus
Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace
Sangamo: Q1 Earnings Snapshot - San Antonio Express-News
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa
Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus
Sangamo hits milestone toward accelerated approval for ST-920 - Fabry Disease News
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - BioSpace
Sangamo Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Zenopa
Sangamo advances gene therapy for Fabry disease By Investing.com - Investing.com India
Sangamo Therapeutics Announces Important Derisking Milestones in - GuruFocus
Sangamo advances gene therapy for Fabry disease - Investing.com
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease | SGMO Stock News - GuruFocus
Sangamo Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Sangamo Therapeutics to Present Neurology Pipeline Advances at t - GuruFocus
Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):